Multiple Myeloma in Relapse

Oncology
6
Pipeline Programs
8
Companies
8
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
2
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Karyopharm Therapeutics
1 program
1
SelinexorPhase 21 trial
Active Trials
NCT04925193Active Not Recruiting18Est. Nov 2026
Molecular Partners
Molecular PartnersSchlieren-Zurich, Switzerland
1 program
1
MP0250 plus BOR+DEXPhase 1/21 trial
Active Trials
NCT03136653Completed33Est. Jan 2021
Bristol Myers Squibb
1 program
1
pomalidomidePhase 1/2
Precision BioSciences
1 program
1
C-4-29 CellsPhase 11 trial
Active Trials
NCT04861480Unknown18Est. Jul 2024
Kelonia Therapeutics
1 program
1
KLN-1010Phase 11 trial
Active Trials
NCT07075185RecruitingEst. May 2042
M&
Merck & Co.RAHWAY, NJ
1 program
1
MK-4002Phase 11 trial
Active Trials
NCT04184050Active Not Recruiting100Est. Dec 2026
Amgen
AmgenTHOUSAND OAKS, CA
2 programs
CarfilzomibN/A1 trial
CarfilzomibN/A1 trial
Active Trials
NCT02970747Completed359Est. Apr 2025
NCT05495620Unknown300Est. Sep 2023
GSK
GSKLONDON, United Kingdom
1 program
Impact of a Health Technology Intervention on Patient Activation in Multiple MyelomaN/A1 trial
Active Trials
NCT05673083Active Not Recruiting200Est. Mar 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Karyopharm TherapeuticsSelinexor
Molecular PartnersMP0250 plus BOR+DEX
Kelonia TherapeuticsKLN-1010
Precision BioSciencesC-4-29 Cells
Merck & Co.MK-4002
GSKImpact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
AmgenCarfilzomib
AmgenCarfilzomib

Clinical Trials (8)

Total enrollment: 1,028 patients across 8 trials

NCT04925193Karyopharm TherapeuticsSelinexor

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Start: Nov 2021Est. completion: Nov 202618 patients
Phase 2Active Not Recruiting
NCT03136653Molecular PartnersMP0250 plus BOR+DEX

A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma

Start: May 2017Est. completion: Jan 202133 patients
Phase 1/2Completed
NCT07075185Kelonia TherapeuticsKLN-1010

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

Start: Jul 2025Est. completion: May 2042
Phase 1Recruiting
NCT04861480Precision BioSciencesC-4-29 Cells

Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma

Start: Jun 2021Est. completion: Jul 202418 patients
Phase 1Unknown
NCT04184050Merck & Co.MK-4002

Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)

Start: Apr 2020Est. completion: Dec 2026100 patients
Phase 1Active Not Recruiting
NCT05673083GSKImpact of a Health Technology Intervention on Patient Activation in Multiple Myeloma

Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma

Start: Mar 2023Est. completion: Mar 2026200 patients
N/AActive Not Recruiting
NCT05495620AmgenCarfilzomib

Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

Start: Aug 2022Est. completion: Sep 2023300 patients
N/AUnknown
NCT02970747AmgenCarfilzomib

Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients

Start: Oct 2016Est. completion: Apr 2025359 patients
N/ACompleted

Related Jobs in Oncology

Operator

Sartorius Stedim Biotech
Shanghai
9h ago

Operator

Sartorius Stedim Biotech
Shanghai
9h ago

Clinical Trials Manager

Tango Therapeutics
Boston, MA
10h ago

Summer intern Neuroscience

Arvinas
New Haven - CT
Yesterday

Scientist (R3)

Pfizer
Ireland - Dublin - Grange Castle
Yesterday

Physician Director Oncology Data Science - Translational Science

GSK
USA - Pennsylvania - Upper Providence
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,028 patients
8 companies competing in this space

Related Indications

Breast Cancer(585)Prostate Cancer(389)Non-small Cell Lung Cancer(388)Multiple Myeloma(363)Cancer(252)Advanced Solid Tumors(229)Acute Myeloid Leukemia(210)Neoplasms(204)Colorectal Cancer(172)Melanoma(172)